Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Teva Pharm expects U.S. opioid case settlements to cost $2.6 billion

Stock Markets May 03, 2022 12:31PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The logo of Teva Pharmaceutical Industries is seen in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen

By Steven Scheer

JERUSALEM (Reuters) -Teva Pharmaceutical Industries believes it would have to pay around $2.6 billion in cash and medicine to settle thousands of lawsuits alleging it and other drug companies fuelled the U.S. opioid epidemic.

On the heels of two more state settlements this year, Israel-based Teva, the world's largest generic drugmaker, raised its legal provision for the opioid litigation by $1.1 billion in the first quarter to $2.6 billion, which would be paid out over 15 years.

"It's the result of a holistic assessment of what's the effect of (state) settlements we have done so far, (and) what's the most likely outcome based on our current negotiations," CEO Kåre Schultz told a conference call of analysts after Teva reported first-quarter profit that met expectations.

Teva in March settled with Florida and Rhode Island, with a bench trial in West Virginia this month and another in San Francisco slated for July. Schultz hopes for a nationwide settlement and there are ongoing negotiations.

"We're getting closer there," Schultz said. "I'm slightly more optimistic on the time schedule now. And that's why I hope that we will see a nationalised settlement before the end of this year."

He told Reuters such a settlement would avoid many more trials that could take years. "If you want to help people suffering from substance abuse, you sort of have to settle because otherwise as long as you haven't settled there's no help coming to people in individual states that have not settled," he added.

Teva agreed to pay $21 million to Rhode Island plus $78.5 million worth of generic versions of overdose treatments Narcan and Suboxone. In Florida, it will pay $177 million plus $84 million in generic Narcan.

Teva's preference for contributing medicines over cash has been a sticking point in settlement talks. Some states and counties have raised concerns that long-term distribution agreements could discourage other companies from devising new forms of treatment. They have also questioned the value of the medicine, produced far more cheaply than the prices used in the settlement agreements.

Teva earned 55 cents per diluted share excluding one-time items in the January-March period, down from 63 cents a share a year earlier.

Hurt by lower sales in North America of both generic drugs and its own multiple sclerosis treatment Copaxone, which is facing stiff competition, revenue fell 8% to $3.66 billion.

Analysts had forecast Teva would earn 55 cents a share ex-items on revenue of $3.76 billion, according to I/B/E/S data from Refinitiv.

Amid currency fluctuations, Teva lowered its 2022 revenue estimate to $15.4-$16.0 billion from $15.6-$16.2 billion, after revenue of $15.9 billion in 2021. It reiterated its projection for 2022 adjusted EPS of $2.40-$2.60, versus $2.58 last year.

Sales of the company's migraine drug Ajovy grew 16% to $36 million and reached a 24% market share, although Schultz said he expects that to rise to 33%. Huntington’s disease treatment Austedo's sales rose 6% to $154 million, with projections of $1 billion in 2022.

Overall generic drug sales in North America dipped 15% to $899 million due to competition on many products.

Revenue in Europe slipped 5% to $1.16 billion, although sales of Ajovy doubled to $30 million.

Teva's net debt fell to $20.7 billion and the company continues to use all its cash to pay down debt.

Its New York-listed shares were up 1.2% at $8.64 at midday.

Teva Pharm expects U.S. opioid case settlements to cost $2.6 billion
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email